Skip to main content

Table 4 Characteristics of BCS Cohort, Overall and by Fracture Status

From: Vertebral fractures among breast cancer survivors in China: a cross-sectional study of prevalence and health services gaps

Variable Overall No Fracture Fracture
Age years 57.5 ± 4.9 57.1 ± 4.8 60.0 ± 5.2b
BMI kg/m2 24.8 ± 3.7 24.9 ± 3.7 23.8 ± 3.3
Education ≥ High School 156/200 (78) 143/178 (80.3) 13/22 (59.1)a
Menarche years 14.4 ± 2.0 14.5 ± 1.9 14.5 ± 2.1
Menopause years 49.4 ± 4.0 49.4 ± 4.2 49.2 ± 2.2
Parity
 0 2/200 (1) 2/178 (1.1) 0/22 (0)
 1 137/200 (68.5) 126/178 (70.8) 11/22 (50)a
  ≥ 2 61/200 (30.5) 50/178 (28.1) 11/22 (50)a
Smoking, Ever 6/200 (3) 6/178 (3.4) 0/22 (0)
Current Alcohol Use 11/200 (5.5) 11/178 (6.2) 0/22 (0)
Fall in Past Year 31/198 (15.7) 28/176 (15.9) 3/22 (13.6)
Parental Fracture History 20/188 (10.6) 18/167 (10.8) 2/21 (9.5)
Personal Fracture History 21/200 (10.5) 19/178 (10.7) 2/22 (9.1)
Calcium Supplement 96/196 (49) 88/174 (50.6) 8/22 (36.4)
DXA Since Diagnosis 54/200 (27) 44/178 (24.7) 10/22 (45.5)a
Low BMD Since Diagnosis 24/195 (12.3) 22/173 (12.7) 2/22 (9.1)
CTx ng/mL 0.458 ± 0.211 0.457 ± 0.209 0.463 ± 0.227
P1NP ng/mL 61.1 ± 30.4 61.3 ± 30.1 58.9 ± 33.2
25OHD ng/mL 20.3 ± 7.8 20.5 ± 7.6 19.0 ± 9.7
Postmenopausal at Diagnosis 81/189 (42.9) 67/167 (40.1) 14/22 (63.6)a
Duration of Breast Cancer 6.3 ± 1.9 6.4 ± 2.0 6.1 ± 1.6
BrCa Stage at Diagnosis
 I 77/183 (42.1) 69/162 (42.6) 8/21 (38.1)
 II 79/183 (43.2) 69/162 (42.6) 10/21 (47.6)
 III 27/183 (14.8) 24/162 (14.8) 3/21 (14.3)
Hormone Receptor Status
 ER+/PR+ 113/186 (60.1) 100/164 (61) 13/22 (59.1)
 ER+/PR- 11/186 (5.9) 10/164 (6.1) 1/22 (4.6)
 ER-/PR+ 33/186 (17.6) 30/164 (18.3) 3/22 (13.6)
 ER-/PR- 29/186 (15.4) 24/164 (14.6) 5/22 (22.7)
HER2 Receptor Positive 38/183 (20.8) 35/161 (21.7) 3/22 (13.6)
Surgery 187/187 (100) 165/165 (100) 22/22 (100)
Radiation Therapy 53/182 (29.1) 45/160 (28.1) 8/22 (36.4)
Chemotherapy 153/185 (82.7) 135/163 (82.8) 18/22 (81.8)
Endocrine Therapy 158/189 (84) 141/167 (84.4) 17/22 (77.3)
 SERM 70/188 (37.2) 64/166 (38.6) 6/22 (27.3)
 Aromatase Inhibitor 90/189 (47.6) 82/167 (49.1) 8/22 (36.4)
 GnRH agonist 2/189 (1.1) 2/167 (1.2) 0/22 (0)
 Ovariectomy 16/189 (8.5) 13/167(7.8) 3/22 (13.6)
Recurrence 2/185 (1.1) 2/162 (1.2) 0/22 (0)
  1. Values for continuous variables are reported as mean ± SD and for categorical values as n/N(%)
  2. PK-VF Peking Vertebral Fracture Study, BCS breast cancer survivors, DXA dual-energy x-ray absorptiometry, BMD bone mineral density, CTx serum β-c-terminal telopeptide of type 1 collagen, P1NP pro-collagen type 1 N propeptide, 25OHD 25-hydroxy vitamin D, ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2, SERM selective estrogen receptor modulator, GnRH gonadotropin releasing hormone
  3. a < .05
  4. b < .01